- Home
- GOSS vs NAT Comparison
GOSS vs NAT Comparison
Compare GOSS & NAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GOSS | NAT |
|---|---|---|
| Founded | 2015 | 1995 |
| Country | United States | Bermuda |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 796.2M | 825.8M |
| IPO Year | 2019 | 1997 |
Fundamental Metrics
Financial Performance| Metric | GOSS | NAT |
|---|---|---|
| Price | $2.51 | $3.91 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 2 |
| Target Price | ★ $8.60 | $3.25 |
| AVG Volume (30 Days) | ★ 5.3M | 2.9M |
| Earning Date | 11-05-2025 | 02-27-2026 |
| Dividend Yield | N/A | ★ 8.70% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | $44,051,000.00 | ★ $294,820,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.41 | $25.84 |
| P/E Ratio | ★ N/A | $434.39 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.76 | $2.13 |
| 52 Week High | $3.87 | $3.93 |
Technical Indicators
Market Signals| Indicator | GOSS | NAT |
|---|---|---|
| Relative Strength Index (RSI) | 34.97 | 70.83 |
| Support Level | $2.35 | $3.36 |
| Resistance Level | $3.87 | $3.51 |
| Average True Range (ATR) | 0.27 | 0.11 |
| MACD | -0.12 | 0.06 |
| Stochastic Oscillator | 12.32 | 96.69 |
Price Performance
Historical ComparisonAbout GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About NAT Nordic American Tankers Limited
Nordic American Tankers Ltd owns and operates double-hull crude oil tankers. It is an international tanker company that owns double-hull Suezmax tankers. It operates vessels in the spot market or on spot market-related charters according to cooperative arrangements with third parties. The company's fleet consists of crude oil tankers, and all of its vessels are employed in the spot market. The company has only one type of vessel - Suezmax crude oil tankers. It operates in markets that are very competitive and based mainly on supply and demand.